Drug Trial Radar · NCT05497843
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 25, 2022
Primary completion
Jan 3, 2025
Study completion Jan 3, 2025
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
Conditions
- Soft Tissue Sarcoma
Interventions
ChiauranibDrug
50mg, orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival of 12 weeks(PFS12w)Time frame: 12 weeks after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.